From Yahoo Finance: 2025-03-29 16:17:00

In a recent article, a list of the 10 Best Mid Cap Biotech Stocks to Buy was published, including an analysis of where Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stands among them. With over 700-800 biotech stocks in the public market, almost a quarter have negative enterprise values, posing challenges for investors. Analysts suggest cutting down on the oversaturation of companies to create more value in the sector. Despite the risky nature of biotech stocks, the potential for high returns is enticing for many investors. In a report, Sarepta Therapeutics, Inc. was highlighted as a compelling buying opportunity, with analysts maintaining a Buy rating and price target of $123.00.



Read more at Yahoo Finance: Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?